Page last updated: 2024-12-10

1H-indol-3-yl(pyridin-2-yl)methanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 1H-Indol-3-yl(pyridin-2-yl)methanol: A Versatile Building Block in Research

1H-Indol-3-yl(pyridin-2-yl)methanol is an organic compound with the chemical formula C14H12N2O. It features both an indole and a pyridine ring, which makes it a versatile building block for synthesizing various biologically active compounds.

**Why is it important for research?**

Here are some key areas where this compound is of interest:

* **Medicinal Chemistry:** The indole and pyridine moieties are commonly found in pharmaceuticals. 1H-Indol-3-yl(pyridin-2-yl)methanol can be used as a starting point for developing new drugs with various therapeutic activities, such as:
* **Anti-cancer agents:** The indole ring has been shown to exhibit anti-proliferative activity against several cancer cell lines.
* **Anti-inflammatory agents:** The pyridine ring is often found in anti-inflammatory drugs.
* **Antimicrobial agents:** Combining the indole and pyridine moieties can lead to compounds with antimicrobial properties.
* **Materials Science:** The compound's aromatic structure allows for potential applications in the development of organic semiconductors and photoactive materials.
* **Synthetic Chemistry:** 1H-Indol-3-yl(pyridin-2-yl)methanol serves as a valuable precursor for the synthesis of a wide range of heterocyclic compounds with diverse functionalities.

**Current research on 1H-Indol-3-yl(pyridin-2-yl)methanol:**

* **Synthesis and Characterization:** Researchers are actively exploring new and efficient synthetic routes to access this compound and its derivatives.
* **Biological Activity Studies:** The compound's potential therapeutic properties are being investigated through various biological assays, including cytotoxicity, antimicrobial, and anti-inflammatory studies.
* **Material Development:** Efforts are underway to explore the potential of this compound in organic electronics and optoelectronics.

**Challenges and Future Directions:**

* **Toxicity and Pharmacokinetic Studies:** More research is needed to evaluate the safety and pharmacokinetic properties of this compound and its derivatives before they can be considered for clinical trials.
* **Structure-Activity Relationship Studies:** Understanding the relationship between the structure of the compound and its biological activity is crucial for designing more potent and selective drugs.
* **Novel Applications:** Continued research may lead to the discovery of new and unexpected applications for this versatile compound.

Overall, 1H-Indol-3-yl(pyridin-2-yl)methanol holds immense potential in medicinal chemistry, materials science, and synthetic chemistry. Further research in these areas could lead to the development of new drugs, materials, and technologies with significant societal impact.

Cross-References

ID SourceID
PubMed CID2810102
CHEMBL ID1376439
CHEBI ID190550

Synonyms (25)

Synonym
STL305052
IFLAB1_005552
OPREA1_145765
MLS000043722 ,
smr000020734
1h-indol-3-yl(pyridin-2-yl)methanol
IDI1_010955
SR-01000606017-2
AKOS000267243
HMS1427M08
CHEBI:190550
HMS2305B14
CCG-48407
(1h-indol-3-yl)(pyridin-2-yl)methanol
F1310-0037
AKOS016038960
1h-indol-3-yl(2-pyridinyl)methanol
1h-indol-3-yl(2-pyridyl)methanol
cid_2810102
bdbm55268
CHEMBL1376439
(indol-3-yl)(pyridin-2-yl)methanol
BRD-A27221145-001-08-7
51626-59-6
Z57213778
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency25.11890.631035.7641100.0000AID504339
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency22.38720.100022.9075100.0000AID485364
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.62340.28189.721235.4813AID2326
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
neutrophil cytosol factor 1Homo sapiens (human)IC50 (µMol)50.00000.39006.544129.1200AID1275
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)100.00007.390021.523843.9000AID624474
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.17 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]